Objective
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise.
A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous prime–boost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic.
To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the “Sclavo Vaccines Association” (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.
Fields of science
- natural sciencesbiological sciencesgenetics
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepathology
Call for proposal
FP7-HEALTH-2011-single-stage
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
53100 Siena
Italy
See on map
Participants (51)
2300 Kobenhavn S
See on map
Participation ended
SW17 0RE London
See on map
80539 Munchen
See on map
75724 Paris
See on map
OX1 2JD Oxford
See on map
53100 Siena
See on map
1211 Geneve
See on map
53100 SIENA
See on map
69007 LYON
See on map
Participation ended
1030 Vienna
See on map
405 30 Goeteborg
See on map
2333 ZA Leiden
See on map
30322 Atlanta
See on map
8219 PK LELYSTAD
See on map
1010 Wien
See on map
98102 Seattle Wa
See on map
3584 CS Utrecht
See on map
20089 Rozzano
See on map
6500 Bellinzona
See on map
00161 Roma
See on map
WC2R 2LS London
See on map
1211 Geneve
See on map
75015 PARIS 15
See on map
75794 Paris
See on map
3015 GD Rotterdam
See on map
53100 Siena
See on map
75001 PARIS
See on map
101 Reykjavik
See on map
00128 Roma
See on map
9 DUBLIN
See on map
0349 OSLO
See on map
Participation ended
3063 ITTIGEN
See on map
421 74 VASTRA FROLUNDA
See on map
3584 CH UTRECHT
See on map
53035 Monteriggioni
See on map
Participation ended
8952 SCHLIEREN
See on map
Participation ended
111 45 STOCKHOLM
See on map
Participation ended
5627 VV EINDHOVEN
See on map
53100 Siena
See on map
SW1W 9SZ London
See on map
98109 5240 SEATTLE WA
See on map
SW7 2AZ LONDON
See on map
GU2 7XH Guildford
See on map
Participation ended
1030 Wien
See on map
Participation ended
1010 WIEN
See on map
6020 Innsbruck
See on map
11145 Stockholm
See on map
53100 Siena Si
See on map
LS2 7UE Leeds
See on map
1030 WIEN
See on map
1330 Rixensart
See on map